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L’immunoterapia rappresenta una valida strategia per le terapie antitumorali e 
antivirali. La tecnologia del phage display ha consentito la produzione di 
immunoagenti completamente umani specifici per antigeni associati a tumore (TAA) 
o per recettori cellulari di superficie essenziali per l’infezione virale.  
Mediante l’uso di tale tecnologia abbiamo isolato frammenti anticorpali 
(scFvs) umani specifici per i loops extracellulari della Claudina-1 (CLDN-1), 
proteina transmembrana che forma tight junctions ed è essenziale per l’ingresso e 
per l’infezione del virus dell’epatite C (HCV). Gli scFvs selezionati sono stati 
convertiti in anticorpi umani con isotipo IgG4 e caratterizzati. Essi mostrano una 
selettiva ed elevata affinità di legame per cellule esprimenti la proteina CLDN-1, 
riconoscono diversi epitopi della proteina ed inibiscono efficientemente con 
modalità dose-dipendente l’infezione da HCV in colture cellulari di epatociti umani.  
Un bersaglio utile per l’immunoterapia del cancro è rappresentato da ErbB2, 
un recettore ad attività tirosina-chinasica iper-espresso su diversi tipi di cellule 
tumorali, tra cui quelle della ghiandola mammaria, mentre è espresso a bassi livelli 
su cellule normali e solo su alcuni tipi di cellule epiteliali.  
Un nuovo frammento anticorpale umano (scFv), chiamato Erbicin, specifico 
per il recettore ErbB2 era stato ottenuto nel nostro laboratorio mediante tecnologia 
del phage display.  
Erbicin è stato fuso ad una variante della ribonucleasi pancreatica umana (HP-
RNasi) resistente all’inibitore delle RNasi, in modo da ottenere una nuova 
immunoRNasi anti-ErbB2, chiamata Erb-HPDDADD-RNasi. In particolare, la 
nuova immunoRNasi è in grado di legare con elevata affinità un pannello di cellule 
tumorali gastriche esprimenti diversi livelli di ErbB2 e di inibire la loro crescita più 
efficientemente rispetto all’immunoRNasi parentale, sensibile all’inibitore. Inoltre, 
Erb-HP-DDADD-RNasi ha mostrato attività citotossica anche per cellule tumorali 
resistenti a Herceptin, sia in vitro che in vivo in modelli sperimentali di topo. 
Simili risultati sono stati ottenuti dalla fusione di Erbicin con il frammento Fc 
di una IgG1 umana in modo da ottenere un costrutto, chiamato Erb-hcAb (anticorpo 
compatto anti-ErbB2) per le sue dimensioni ridotte (100 kDa), rispetto a quelle di 
una IgG umana (155 kDa).   
Nel presente lavoro abbiamo studiato gli effetti anti-tumorali su cellule di 
carcinoma gastrico di Erb-hcAb, che è in grado di riconoscere un epitopo di ErbB2 
diverso rispetto a quello di trastuzumab (Herceptin) e pertuzumab (Omnitarg), gli 
unici anticorpi anti-ErbB2 attualmente in uso clinico per la terapia del carcinoma 
mammario. I risultati dimostrano che la crescita di cellule tumorali gastriche è 
efficientemente inibita sia in vitro che in vivo da Erb-hcAb, il quale mostra un 
effetto antitumorale sulla linea cellulare NCI-N87 anche più potente di quella 
osservata per Herceptin. 
In conclusione, tali nuovi immunoagenti umani possono rappresentare un 
valido strumento per la terapia antitumorale e antivirale in associazione o in 
alternativa alle attuali terapie convenzionali.  
Summary 
Immunotherapy is a precious strategy to fight cancer and viral infections. 
Phage display technology allows for the production of fully human immunoagents 
specific for tumor associated antigens (TAA) or for cell surface receptors involved 
in virus infection.  
By using this technology we isolated fully human antibody fragments (scFvs) 
specific for the extracellular loops of Claudin-1 (CLDN-1), a tight junction protein 
essential for hepatitis C virus (HCV) cell entry and following infection. The selected 
scFvs have been converted in human IgG4 antibodies and characterized. They show 
high selective binding affinities for CLDN-1-positive cells, recognize distinct 
epitopes of the protein, and specifically inhibit HCV infection in a dose-dependent 
manner in cell cultures of human hepatocytes.  
An attractive TAA for cancer immunotherapy is ErbB2, a tyrosine kinase 
receptor overexpressed on many different types of tumor cells, such as breast and 
gastric cancer, whereas it is expressed at low levels on normal cells and only on 
certain epithelial cell types.  
A human antibody fragment (scFv), named Erbicin, specific for ErbB2 
receptor has been isolated in our laboratory by using phage display technology.  
Erbicin was fused with a human pancreatic RNase (HP-RNase) variant 
resistant to the cytosolic inhibitor, to obtain a novel anti-ErbB2 immunoRNase (IR), 
which was called Erb–HPDDADD-RNase. The novel IR binds with high affinity to 
a panel of ErbB2-positive gastric tumor cells and inhibits their growth more 
efficiently than the parental immunoRNase, which is not resistant to the inhibitor. 
Moreover, Erb–HP-DDADD-RNase is endowed with an antitumor activity for 
Herceptin-resistant cancer cells both in vitro and in vivo. 
Similar results were obtained fusing Erbicin with the Fc region of a human 
IgG1 to obtain a construct, which was called Erb-hcAb for its compact size (100 
kDa) if compared with the full size (155 kDa) of a natural IgG.  
Here we report on the antitumor effects on gastric cancer cells of Erb-hcAb 
which targets a different epitope of ErbB2 with respect to trastuzumab (Herceptin) 
and pertuzumab (Omnitarg), the only anti-ErbB2 antibodies currently in clinical use 
for breast cancer therapy. The results demonstrate that the growth of gastric cancer 
cells is efficiently inhibited in vitro and in vivo by Erb-hcAb, which shows antitumor 
effects on the NCI-N87 cell line more potent than those observed for Herceptin.  
In conclusion, these human immunoagents may represent valuable tools for 
both antitumor and antiviral therapies in association or in alternative to conventional 
therapies currently used. 
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INTRODUCTION 
 
 
1.  Human antiviral immunoagents 
 
1.1. Hepatitis C Virus 
Hepatitis C virus (HCV) infection is one of the most common global 
health diseases. HCV is a member of the Flaviviridae family and Hepacivirus 
genus. The virion contains a single-stranded positive RNA with a length of 
about 10.000 nucleotides, consisting of a single ORF which is encapsulated 
by an icosahedral capsid and an external lipid envelope. HCV is a 
heterogeneous virus, classified into 7 genotypes and more than 50 subtypes 
with a genome variability of 30-35% among genotypes, and of 20-25% 
among subtypes (1).  
This genetic variability in the virus populations provides a survival 
advantage to the virus by creation of multiple variant genomes and a high 
rate of variant generations, that allow for a rapid selection of mutants in new 
environmental conditions.  
In the virus genome there are two UTRs located at the 5’ and 3’ termini 
called cis-active RNA elements which are essential for protein translation. A 
single precursor polyprotein is approximately composed by 3010 aminoacids, 
cleaved into 10 different proteins. Structural Core proteins, E1, E2 and p7 are 
released from the polyprotein after cleavage by cellular proteases; the non-
structural proteins such as NS2, NS3 and NS4A are produced by virus-
encoded proteases (2, 3). 
The E1 and E2 envelop proteins are highly glycosylated and play an 
important role in cell entry,  which is a slow and complex process consisting 
of many steps. The initial attachment of the viral protein E2 is to 
glycosaminoglycans (GAGs) and Low Density Lipoprotein receptor (LDL-
R), followed by interaction with a complex formed by SR-BI and CD81. 
Virus associated to CD81 is subsequently transferred to tight junctions due 
the association of CD81 with CLDN-1. HCV enters the cell by clathrin-
mediated endocytosis and, upon acidification, the fusion of the virus 
envelope leads to the release of the viral genome into the cytoplasm (4) 
(Figure 1). 
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Fig. 1 - HCV structure and its cell-entry mechanism 
 
Claudins are the most important structural and functional components 
of tight junction integral membrane proteins expressed in all epithelial 
tissues, with at least 24 members in mammals. They are crucial for the 
paracellular flux of ions and small molecules. Claudin-1 (CLDN-1) is 
expressed predominantly in the liver, where it localizes both at tight 
junctional (apical-canalicular) and extrajunctional (basolateral-sinusoidal) 
sites of hepatocytes, but predominantly at the apical site.  
The structure of Claudin-1 consists of four transmembrane helices, with 
a very short intracellular N-terminal sequence (2–6 residues), two 
extracellular loops, and an intracellular C terminal tail (5) (Figure 2). The 
first loop influences paracellular charge selectivity (6), the second loop is the 
receptor for a bacterial toxin (7), and the C terminus binds to cytoplasmic 
proteins through a PDZ motif (8).  
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Fig. 2 - Schematic representation of CLDN-1 
 
Recent studies confirm that CLDN-1 is required for late step of HCV 
entry in the post-binding phase of infection, subsequent to HCV binding to 
CD81 and SR-BI (9). Indeed the expression of CLDN-1 confers susceptibly 
to HCVpp infection in non-hepatic cell lines such as HEK t293 and SW13. 
Moreover, silencing of CLDN-1 inhibits HCV infection in susceptible cells 
(Huh7.5) (9). 
Other studies indicate that distribution of CLDN-1 in tight junctions 
correlates with permissiveness to HCV infection (10, 11), thereby confirming 
that localization of CLDN-1 at tight junctions is critical for viral entry and 
HCV cellular tropism. In fact, while viral cell entry is undoubtedly essential 
for initiation of infection, direct cell-cell transmission (in which it is involved 
CLDN-1) probably constitutes the dominant mechanism of viral spread and 
persistence of infection (12, 13). 
 
 
1.2.HCV Epidemiology and therapy 
Direct contact with infected blood and blood products, sexual 
relationships and use of injectable drugs are the main ways of HCV infection. 
Recent estimates indicate that 500.000 deaths are associated with HCV 
infection worldwide (14). The major burden of HCV infection derives from 
chronic infection, as 3-4 million people are newly infected each year and 170 
million people are chronically infected (15) with the risk of developing liver 
disease including cirrhosis, fibrosis and liver carcinoma (50-76% of all liver 
cancers) which are the prime reason for liver transplants.  
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In the next future, the proportion of all US HCV cases with liver 
cirrhosis is estimated to become even larger than the current levels (16), thus 
resulting in an increased need for liver transplantation.  
The mechanism by which HCV escapes the immune responses and 
establishes a chronic infection are not completely defined. HCV replicates at 
high rate (17) and its RNA-dependent RNA polymerase lacks proofreading 
capacity. This results in high genetic variability, which allows for rapid 
evolution under selection either by the immune system or in the presence of 
antiviral drugs. Thus, the emergence of resistance is the major hurdle that 
needs to be overcome in developing new therapeutic approaches against 
HCV. 
The current standard of care, i.e. a combination of Pegylated-Interferon 
alpha and Ribavirin (PegIFN/RBV) is effective in only about 50% of patients 
and is often poorly tolerated (18). There is an acute need of new therapies 
especially for patients that undergo liver transplantation (LT) for HCV-
related liver disease. Almost all of these patients suffer from graft re-
infection, they are difficult to treat, respond less well and it is often necessary 
to wait several months after LT before starting therapy (19). 
Although new anti-viral drugs targeting the virus protease or 
polymerase, such as telaprevir or boceprevir in clinical use since 2011, have 
been either approved or in clinical development, the available pre-clinical 
and clinical data already indicate that side toxic effects of the individual 
compounds and drug-resistant variants emerge during treatment (20 - 24).  
Thus, antibodies that are capable of preventing HCV infection are an 
attractive novel therapy based on a different mechanism of action. There are 
at least two major therapeutic settings that would greatly benefit from an 
effective antibody based therapy: 
1) in chronically infected patients:  in combination with PegIFN/RBV 
to increase the number of responders, or in combination with novel anti-viral 
drugs to prevent re- infection by drug-resistant mutants; 
2) in patients undergoing LT: as a monotherapy during the anhepatic 
phase and during the first days/weeks following transplantation to prevent re-
infection of the graft; in combination with PegIFN/RBV, during the 
anhepatic phase and during the first days/weeks following transplantation to 
increase the number of responders.  
HCV displays a very high inter- and intra- individual genetic variability 
especially in the E1 and E2 envelope glycoproteins where neutralizing 
determinants are present. Therefore antiviral neutralizing antibodies are 
effective at best against only a small number of viral variants (15). 
Accordingly, passive immunotherapy in LT patients with polyclonal or 
monoclonal antibodies against the viral envelope can only transiently lower 
RNA levels, but do not prevent re-infection presumably due to the large 
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heterogeneity in the infecting viral population (25, 26). In addition, it was 
shown that HDL can reduce the neutralizing effec t of anti-HCV antibodies 
(27, 28) raising additional concerns about the efficacy of anti-HCV 
antibodies for active or passive immunotherapy. 
For the reasons mentioned above, the recent discovery of cell surface 
molecules required for HCV viral entry offer a novel perspective for the 
development of new preventative and therapeutic agents, suggesting that viral 
cell entry could become a promising antiviral target complementary to targets 
of current standard of care and new antiviral drugs.  
Four different cell surface receptors have been shown to be necessary 
for HCV infection in the hepatocyte: the tetraspannin CD81, the human 
scavenger receptor class B type I (SR-BI), the tight junction Claudin-1 and 
Occludin (29 - 33).  
Antibodies against CD81 (of mouse origin) and SR-BI (of both mouse 
and human origin) have been generated and have shown to be capable of 
inhibiting HCV infection in vitro (a-CD81 and a-SR-BI) and in vivo (a-SR-
BI) when used at very high doses (not feasible for their use for therapy in 
humans). Human monoclonal antibodies against Claudin and Occludin are 
not yet been reported, but some anti-CLDN-1 antibodies have been raised by 
genetic immunization of Wistar rats and found to efficiently inhibit infection 
by HCV of all major genotypes by blocking  cell entry (34).  
As a further progress in the field we describe here the selection b y 
phage display on live cells (35, 49) of a panel of novel high affinity fully 
human monoclonal antibodies directed to Claudin-1 that could be used for 
prevention and therapy of HCV infection.  
We show here that they recognize different epitopes and are endowed 
with anti-HCV inhibition activity when used either alone or in combination 
to prevent HCV infection in cell cultures of hepatocytes in vitro.  
Such mAbs may represent interesting candidates for clinical 
development in HCV therapy of chronic infection and in post-transplant 
setting. 
 
 
2. Human immunoagents for cancer immunotherapy 
 
Cancer is one of the most common diseases in developed countries with 
approximately 20% of deaths per year in the world (36). The absence of 
selectivity for tumor cells is the main limit of the conventional anti-cancer 
treatments, such as chemotherapy and radiotherapy. For this reason 
immunotherapy, based on the use of monoclonal antibodies (mAb) specific 
for tumor associated antigens (TAA) overexpressed on tumor cells, has been 
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shown to be an effective tool for the treatment of certain carcinomas. The 
transmembrane tyrosine kinase receptor ErbB2, overexpressed on tumor cells 
of different origin, such as breast, ovary, lung (37, 38) and gastric cancer, has 
been considered a very attractive target for cancer immunotherapy (39). 
In particular, the overexpression of ErbB2 and its heterodimerization 
with ErbB3 on tumor cells, leads to the activation of the signaling pathways 
promoting cancer growth and survival, such as mitogen-activated protein 
kinase (MAPK) and phosphatidylinositol-3-kinase pathways (PI3K) (Fig. 3). 
 
 
Fig. 3 - ErbB2 signaling pathway 
Herceptin, a humanized monoclonal antibody widely used for 
immunotherapy of ErbB2-positive carcinomas (40) is the first ErbB2-targeted 
therapeutic immunoagent approved by the United States Food and Drug 
Administration. Herceptin is currently in clinical use with some success for 
breast cancer, but it may cause cardiotoxicity and a high fraction of patients 
develop resistance to Herceptin treatment (41 - 43).  
Large-scale clinical studies have shown that 7 or 28% of patients suffer 
from cardiac dysfunction when Herceptin is used alone or in combination 
with anthracyclines, respectively (44 - 46). 
The underlying mechanism of Herceptin cardiotoxicity is based on its 
capacity to inhibit the neuregulin (NRG-1) mediated heterodimerization of 
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ErbB2/ErbB4 on cardiac cells, thus interfering with the pathway of myocyte 
survival, induced by ErbB2 (47). To overcome the limits of Herceptin, novel 
anti-ErbB2 immunoagents have been developed in our laboratory by phage 
display technology. This methodology allows for the isolation of fully human 
antibody fragments, which are the minimal portion of an antibody capable of 
binding to the antigen. A single chain variable fragment (scFv) is made up of 
the variable domains of the heavy (VH) and light chains (VL) connected by a 
flexible oligopeptide. This fragment retains the binding specificity for the 
antigen but is able to diffuse more easily into the tumor masses.  
With the aim of obtaining a novel fully human anti-ErbB2 antibody 
devoid of cardiotoxic side effects, a human ErbB2-specific scFv was isolated 
in our laboratory in collaboration with a research group of the Imperial 
College of London. This scFv, named Erbicin, binds to the cells 
overexpressing ErbB2, by recognizing a distinct epitope from that of 
Herceptin and pertuzumab (48); it is internalized through receptor mediated 
endocytosis, and selectively inhibits the proliferation o f ErbB2-positive 
tumor cells (49). 
 
Erbicin was fused with the Fc region of a human IgG1 (50) to obtain a 
construct, which was called Erb-hcAb for its compact size (100 kDa) if 
compared with the full size (155 kDa) of a natural IgG (Fig. 4). This 
construct should acquire the immuno-effector functions of the Fc domain 
while retaining the ability to diffuse more easily in the tumor masses due to 
its reduced molecular size with respect to a full size antibody.   
Erb-hcAb selectively binds to breast tumor cells expressing ErbB2 and 
inhibits their growth in vitro and in vivo, with no effects on ErbB2-negative 
cells. Moreover, Erb-hcAb is endowed with both antibody dependent cellular 
cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) (49, 
51). Interestingly, Erb-hcAb does not cause cardiotoxic effects, both in vitro 
on rat cardiomyoblast and human cardiomyocytes and in vivo in a mouse 
model, unlike Herceptin that it was shown to be strongly toxic (47, 52 - 54). 
Infact Herceptin, in contrast to Erb-hcAb, induces apoptosis in cardiac 
cells and inhibits the ErbB2-ErbB4 heterodimerization mediated by 
Neuregulin-1 (47). 
Furthermore, Erb-hcAb is active in vitro and in vivo against some 
ErbB2-positive breast cancer cell lines resistant to Herceptin (55).  
To validate Erb-hcAb as a therapeutic agent, we analyzed its inhibitory 
effects also on gastric tumor cells expressing ErbB2, which have been 
reported to be less sensitive to Herceptin treatment (49, 50, 55). 
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Fig. 4 - Schematic representation of anti-ErbB2 immunoagents  
 
As an alternative strategy scFvs can be conjugated with rad ionuclides 
or toxins (56, 57), combining the potent toxicity of these molecules with the 
antigen specificity of antibodies (58). However, the so called 
“immunotoxins” could cause non-specific toxicities, such as vascular leak 
syndrome and hepatotoxicity, thus limiting the therapeutic potential of these 
immunoconjugates (59, 60). 
To circumvent these problems, the toxin has been replaced by a non-
toxic and non- immunogenic RNase, which becomes toxic only upon its 
internalization in the target cells mediated by the antibody moiety (61, 62). 
In our laboratory a novel fully human immunoRNase, named ERB-HP-
RNase, was obtained by fusing Erbicin with human pancreatic RNase (63). 
This immunoconjugate retains both the Erbicin binding affinity to 
ErbB2-positive cells, and the enzymatic activity of native human pancreatic 
RNase. When tested in vitro and in vivo, ERB-HP-RNase was able to 
discriminate between target and non-target cells, and to specifically inhibit 
the proliferation of ErbB2-positive tumor cells either sensitive or resistant to 
Herceptin treatment (51, 55, 63). 
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However, ERB-HP-RNase was found to be sensitive to the neutralizing 
action of the cytosolic RNase inhibitor (RI), a 50 kDa monomeric protein 
present in the cytosol of mammalian cells, which inhibits the ribonucleolytic 
activity of all monomeric members of the human pancreatic RNase family 
(64 - 66). 
Thus, to develop a more potent immunoRNase, Erbicin was fused with 
an inhibitor-resistant variant of human pancreatic RNase.  
The variant RNase was designed to suppress, through Coulombic 
repulsion, its binding to RI, by the replacement of 5 aminoacidic residues 
crucial for the formation and the stability of the RI-RNase complex 
(R39D/N67D/N88A/G89D/R91D) (67).  
The chimeric protein, named ERB-HP-DDADD-RNase (Fig. 4), was 
found to retain the high binding affinity to ErbB2-positive cells of Erbicin, as 
well as the enzymatic activity of the RNase moiety (68). Here we report that 
ERB-HP-DDADD-RNase is capable to discriminate between target and non-
target cells, and to specifically inhibit the proliferation of ErbB2-positive 
cells with a more potent effect than the parental IR. Its antitumor potential 
has also been investigated in vivo in mice implanted with ErbB2-positive 
tumors resistant to Herceptin treatment.  
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MATERIALS AND METHODS 
 
1. Cell Cultures 
The eukaryotic Human Embryonic Kidney HEK t293, HEK 293 
EBNA, the Huh-7.5 human hepato cellular carcinoma and Huh-7 human 
hepatoma cell lines were cultured in Dulbecco's Modified Eagle's medium 
(DMEM, Life Technologies, Inc., Paisley, U.K.) with the addition of non 
essential aminoacid solution (Gibco, Life Technologies, Inc., Paisley, U.K.). 
The HEK t293 cells transduced with the gene encoding C laudin-1 were 
grown in DMEM containing Blasticidin (2 µg/ml) (Gibco, Life Technologies, 
Inc.). The  Chinese hamster ovary (CHO) cells (American Type Culture 
Collection, Rockville, MD, USA) were cultured in F12 medium (Gibco, Life 
Technologies, Inc.).  
The human breast cancer SKBR3 cell line, the human epidermoid 
carcinoma A431 cell line and  the human gastric cancer cell lines (NCI-N87, 
MKN-7, MKN-45 and AGS) were cultured in RPMI medium (Gibco, Life 
Technologies, Inc.). The KPL4 cell line from the malignant pleural effusion 
of a breast cancer patient with an inflammatory skin metastasis, and the 
JIMT-1 cell line established from a pleural metastatis of a 62-year-old breast 
cancer patient resistant to Herceptin were grown in DMEM (Gibco).  
Media were supplemented with 10% FBS, 50 units/ml penicillin, and 
50 µg/ml streptomycin  (All from Gibco, Life Technologies, Inc.).  
 
2. Antibodies 
The following antibodies were used: mouse HRP-conjugated anti-M13 
monoclonal antibody (GE Healtcare Bio-Sciences AB, Uppsala, Sweden); 
mouse HRP-conjugated anti-c-myc-tag monoclonal antibody (Miltenyi 
Biotec Inc., Auburn, U.S.A.); mouse anti-Claudin-1 (C-terminal end) 
monoclonal antibody (Life Technology, Inc.);  rabbit anti- loop 1 of Claudin-1 
polyclonal antibody, (Abcam, Cambridge, U.K.); goat HRP-conjugated anti-
Human IgG (Promega Corporation Madison, U.S.A.); goat HRP-conjugated 
anti-human Fc monoclonal antibody (Immuno Reagents, Inc., Raleight 
U.S.A.); mouse HRP-conjugated anti-His monoclonal antibody (Qiagen 
GmnH, Hilden, Germany), rabbit anti-HER2 monoclonal antibody (Cell 
Signaling Technology, Danvers, MA, USA), rabbit anti-actin polyclonal 
antibody (Sigma-Aldrich), rabbit HRP-conjugated anti- immunoglobulins 
from goat antiserum (Thermo Scientific, Rockford, IL, USA); rabbit anti-Akt 
antibody, rabbit anti-phospho-Akt antibody, rabbit anti-p44/42 MAPK 
(Erk1/2) antibody, rabbit anti-Phospho-p44/42 MAPK (Erk1/2) 
(Thr202/Tyr204) antibody (All from Cell Signaling Technology, Inc.).  
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3. Bacterial Culture Media  
2xTY and LB (Luria-Bertani) culture media were used for the growth 
of bacteria. These media were prepared as described by Sambrook et al. (69). 
 
4. Bacterial Strains 
For the production of the scFv expressed as a fusion with pIII protein of 
the phage, E.Coli TG1 bacterial strain was used; for expression of the scFv as 
a soluble protein, E.Coli SF110 bacterial strain was used.  
The E. coli DH5α (Invitrogen, Life Technologies, Paisley, UK) and 
BL21 DE3 (Novagen-Merck Millipore, Darmstadt, Germany) strains were 
used for cDNA amplification and expression of immunoRNase, respectively.  
 
5. Antibiotics 
The Antibiotics used were Ampicillin (100 µg/ml) and Kanamicin (25 
µg/ml). 
 
6. Preparation of Phage Particles from the Phagemid library 
Phagemid particles were rescued with M13-K07 from the library, as 
described previously (70). Briefly, the phage library was grown in 200 ml of 
2xTY containing 100 µg/ml of Ampicillin and 1% glucose, until the optical 
density at 600nm (OD600) was 0.5. Subsequently, 1 x 109 plaque-forming 
units of M13-K07 helper phage encoding trypsin-cleavable pIII, were added 
to 25 ml of  bacterial culture and incubated for 1 hour at 37°C without 
shaking. Then the cells were centrifuged at 4000 rpm/min for 15 min, 
resuspended in 500 ml of  2xTY containing 100 µg/ml of ampicillin and 25 
µg/ml of kanamycin and grown overnight by shaking at 30°C.  Phage 
particles were purified and concentrated by two steps of polyethylene glycol 
(PEG) precipitation (69) and washed with 20 ml of sterile water. After an 
additional PEG-precipitation step, phages were resuspended in PBS, 
centrifuged at 12,000 rpm for 15 min, and stored at 4°C until  use.  
 
7. Selection of scFv-Phages on live cells 
The human Huh-7.5 cell line, naturally expressing high levels of 
Claudin 1, the HEK t293 cells untrasduced or trasduced with Claudin-1 and 
the CHO cells untrasfected or trasfected with a vector encoding Claudin-1 
were detached with the cell dissociation solution (Sigma-Aldrich, Saint 
Louis, U.S.A.) and washed twice with PBS. For each round of panning, 
phages (1013 cfu) were blocked with 5% milk powder (Sigma-Aldrich) in 
PBS for 15 minutes. The blocked phages were submitted to two following 
rounds of negative selection by two successive incubations with CLDN-1-
negative cells (1 x 106), carried out by gently rotating the suspension for 2 
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hours at 4°C. The unbound phages, collected by centrifugation at 1200 rpm 
for 10 minutes, were then used for the positive selection performed by using 
CLDN-1 trasduced HEK t293 (1 x 106), or Huh-7.5 cells (1 x 106), incubated 
for 16 hours by gently rotating at 4 °C. Cells were then recovered by 
centrifugation at 1200 rpm/min for 10 minutes and washed twice with PBS. 
The positive selection on CLDN-1 trasfected CHO cells was carried out by 
incubating the phages with of 2 x 106 adherent cells. After extensive washes 
with PBS, bound phages were eluted from positive cells with a solution of 1 
µg/ml of Trypsin (Sigma-Aldrich), which was then stopped by  the addition 
of complete EDTA-free protease inhibitor (Roche Diagnostic, Mannheim, 
Germany). The recovered phages were amplified by infecting E.Coli TG1 
cells to prepare phages for the next round of selection.  
 
8. Preparation of scFv-phages for cell ELISA 
A TG1 culture was infected with the eluted phages (after 3-4 rounds of 
panning) and plated on 2xTY/agar containing 1% glucose and ampicillin (100 
µg/ml). Individual clones were picked, transferred into 96-well plates and 
grown in 100 μl of 2xTY medium containing 1% glucose and ampicillin (100 
μg/ml) for 18 hours in agitation at 37°C. Glycerol (20 %) was added to each 
well of these master plates before storage at -80°C. Replicas of the master 
plates were prepared and the scFv-phages were produced by superinfection 
with M13-K07 helper phage encoding trypsin-cleavable pIII as described 
above. The plates were centrifuged at 1200 rpm for 30 minutes at 4°C to 
pellet the bacteria, and aliquots of 50 μl of scFv-phage-containing 
supernatants were used for cell ELISA.  
 
9. Analysis of positive clones 
Positive clones selected by cell ELISA were inoculated in 10 ml of 
2xTY containing 100 µg/ml of Ampicillin and 1% glucose and grown up 
over night by shaking at 37°C to prepare the plasmids by using QIAprep Spin 
Miniprep Kit (QIAGEN, Venlo, Limburg, Netherlands). To determine the 
number of individual selected clones, the  cDNA encoding the single chain 
variable fragment of positive clones was amplified by PCR from pCANTAB 
or pHEN2 plasmid, using the following forward primers: 5’-
TTATTATTCGCAATTCCTTTAGTT-3’ and 5’-
ATGAAATACCTATTGCCTACG 
GCAGCCGCTGGATTGTTATTACTCGCGGCCCAGCCGGCCATG
GCC-3’ respectively, both complementary to the pel B leader sequence, 
located upstream the heavy variable region (VH) sequence, and a reverse 
primer 5’-CTCTTCTGAGATGAGTTTTTG-3’, Mycseq, complementary to 
the sequence located downstream to the c-myc tag peptide. Reactions were 
performed with Taq DNA polymerase (Expand High Fidelity PCR System, 
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Roche Diagnostic) in a volume of 50 µl for 35 cycles under the following 
conditions: 45 seconds denaturating at 95°C, 30 seconds annealing at 60°C 
and 45 seconds extension at 72°C. The amplified products were analyzed by 
electrophoresis on 1% agarose gel. The nucleotide sequences encoding scFvs 
were determined by using the same PCR primers by an external facility (Bio-
Fab Research srl, Rome, Italy). The sequences were analyzed with a software 
for DNA and amino acid editing and alignments (GENtle-software, Magnus 
Manske, University of Cologne, Germany). 
 
10. Soluble scFv expression and Purification 
Cultures of E. Coli SF110 infected with each of the anti-CLDN-1 scFv-
phage preparation were grown in 200 ml of 2xTY medium containing 100 
µg/ml ampicillin, until an absorbency of 0,8 optical density was reached. The 
expression of soluble scFv was induced by the addition of IPTG (1mM) 
(AppliChem GmbH, Darmstadt, Germany) to cell culture, which was then 
grown by shaking at room temperature for 16 hours. Cells were harvested by 
centrifugation at 4000 rpm for 20 minutes and resuspended in B-PER buffer 
(Pierce, Rockford, IL) for 20 minutes by gently rotation at room temperature.  
Cell suspensions were then centrifuged at 12000 rpm for 30 minutes at 4°C to 
obtain the periplasmic extract. Soluble scFvs were purified on immobilized-
metal affinity chromatography, by incubating the periplasmic extract with Ni-
NTA agarose (QIAGEN) for 2 hours by gently rotation. After extensive 
washes with PBS containing imidazole (20 mM) , the protein was eluted in 
NaH2PO4 buffer (50 mM, pH 8.0) containing NaCl (0.3 M) and imidazole 
(250 mM). The purity of the final preparation was evaluated by SDS-PAGE 
followed by Coomassie staining. Purified scFvs, analyzed also by Western 
blotting, were detected by using a mouse HRP-conjugated anti-c-myc-tag 
monoclonal antibody (Miltenyi Biotec Inc.).  
 
11. Production and Purification of mAbs 
For the conversion of the selected scFvs into mAbs In-Fusion™ HD 
cloning kit (Clontech Laboratories, Inc. A Takara Bio Company, Mountain 
View, CA, U.S.A.) was used. This technology fuses DNA fragments, e.g. 
PCR-generated sequences and linearized vectors, efficiently and precisely by 
recognizing a 15 bp overlap at their ends. This 15 bp overlap can be 
engineered by designing primers for amplification of the desired sequences. 
To this aim appropriate primers were designed either complementary to the 
ends of the linearized vector (restriction sites are underlined) or to those of the 
variable-region-fragment sequences with 15 bp extensions homologous to 
vector ends.  
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mAb A2 primers: 
VH FOR   5’-CTCTCCACAGGCGCGCACTCCCAGGTGCAGCTGGTGCAGT-3’ 
VH REV   5’-GGCATTGGGT GGATCCGTCGACAGGACTCACCCACGGTGACCAGGGTACCTTGGCCCC-3’ 
VL FOR   5’-CTCCACAGGCGTGCACTCCGAGCTGACTCAGGACCCTGCT-3’ 
VL REV   5’-TTCTGACTCACCTAGGACGGTCAGCTTGGTCCCTCCGCCGAA-3’ 
 
mAb B9x primers: 
VH FOR   5’-CTCTCCACAGGCGCGCACTCCGAGGTGCAGCTGTTGGAGT -3’ 
VH REV   5’-GGCATTGGGT GGATCCGTCGACAGGACTCACCACTCGAGACGGTGACCATTGTCCC-3’ 
VL FOR   5’-CTCCACAGGCGTGCACTCCCTTTCTTCTGAGCTGACTCAGGAC-3’ 
VL REV   5’-TTCTGACTCACCTAGGACGGTGACCTTGGTCCCTCC-3’ 
 
mAb D10x primers: 
VH FOR   5’-CTCTCCACAGGCGCGCACTCCGAGGTGCAGCTGTTGGAGT -3’ 
VH REV   5’-GGCATTGGGT GGATCCGTCGACAGGACTCACCACTCGAGACGGTGACCATTGT CCC-3’ 
VL FOR   5’-CTCCACAGGCGTGCACTCCCAATCTGCCCTGACTCAGCCT -3’ 
VL REV   5’-TTCTGACTCACCTAGGACGGTCAGCTTGGTCCCTCC-3’ 
 
mAb H9C1 primers: 
VH FOR   5’-CTCTCCACAGGCGCGCACTCCGAGGTGCAGCTGTTGGAGT -3’ 
VH REV   5’-GGCATTGGGT GGATCCGTCGACAGGACTCACCACTCGAGACGGTGACCATTGTCCC-3’ 
VL FOR   5’-CTCCACAGGCGTGCACTCCCTTTCTTCTGAGCTGACTCAGGAC-3’ 
VL REV   5’-TTCTGACTCACCTAGGACGGTGACCTTGGTCCCTCC-3’ 
 
mAb F7C2 primers: 
VH FOR   5’-CTCTCCACAGGCGCGCACTCCGAGGTGCAGCTGTTGGAGT -3’ 
VH REV   5’-GGCATTGGGT GGATCCGTCGACAGGACTCACCACTCGAGACGGTGACCAGGGTGCC-3’ 
VL FOR   5’-CTCCACAGGCGTGCACTCCCAGTCTGTGCTGACTCAGCCA-3’ 
VL REV   5’-TTCTGACTCACCTAGGACTAGTACGGTTCAGCTTTGTTCCTC-3’ 
 
mAb E9C2 primers: 
VH FOR   5’-CTCTCCACAGGCGCGCACTCCGAGGTGCAGCTGTCGGAGT -3’ 
VH REV   5’-GGCATTGGGT GGATCCGTCGACAGGACTCACCACTCGAGACGGTGACCATTGTCCC-3’ 
VL FOR   5’-CTCCACAGGCGTGCACTCCCTTGAAATTGTGTTGACGCAGTCT-3’ 
VL REV   5’-TTCTGACTCACCTAGGACTTTAATCTCCAGTCGTGTCCCTTG-3’ 
 
PCR reaction products were purified by 1% agarose gel by QIAquick 
Gel Extraction Kit (QIAgen) and inserted in the appropriate vectors by using 
the in-Fusion HD Enzyme Premix, according to the manufacturer’s 
reccomendations. The VH sequences were cloned in the linearized PEU 8.2 
vector, previously digested by using BamH1 and BssHII restriction 
endonucleases; VL sequences were cloned in linearized PEU 4.2 vector, 
previously digested  by using ApaL1 and AvrII restriction endonucleases. A 
sequence analysis was then performed to confirm the successful cloning of 
the inserted sequence with the correct reading frame.  
Aliquots of 100 µg of the recombinant vectors encoding each VH and 
VL pair were co-transfected in HEK 293-EBNA by using Lipofectamine® 
Transfection Reagent (Life Technologies, Inc.) and grown up for 10 days in 
150 mm tissue culture dish in a humidified  incubator at 37°C with 5% CO2. 
The antibodies secreted in the medium were purified by using HiTrap 
Protein-A HP (GE Healthcare life sciences, New York, U.S.A.) equilibrated 
in a phosphate-based buffer, pH 8.0 (binding buffer). After extensive washes, 
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the bound antibodies were eluted in a Tris-Glycine buffer, pH 2.5 and readily 
neutralized with the addition of 1 M Tris solution at pH 8.0. The 
concentration of the purified antibodies were determined by BCA Protein 
Assay kit (Pierce, Thermo Fisher Scientific). The purity of the final 
preparations was evaluated by SDS-PAGE and following staining with 
Coomassie blue solution (20% isopropanol, 10% acetic acid, 0.1% 
Coomassie blue). 
 
12. Cell ELISA assay 
To confirm the binding specificity for Claudin-1 of the selected scFv-
phages or purified mAbs, cell ELISA analyses were carried out by using 
CLDN-1-positive and -negative cells. Briefly, the cells were detached with 
non-enzymatic cell dissociation solution (Sigma-Aldrich), washed and 
resuspended in PBS/BSA 6% and plated in 96 multiwell plates (2 x 105 cells 
for each well).  
The scFv-phages or mAbs were then added and incubated in PBS/BSA 
3% for 90 minutes in agitation at room temperature.  For the binding 
detection, cells were incubated for 1 hour either with 100 μl  of PBS buffer 
containing 4% FBS and  mouse HRP-conjugated anti-M13 monoclonal 
antibody (1:5000 dilution) for scFv-phage detection, or with 100 μl of PBS 
buffer containing 3% BSA and goat HRP-conjugated anti-human IgG 
(1:2500 dilution, Promega) for mAbs detection. After 3 washes with PBS, 
cells were finally resuspended  in 50 µl of TMB reagent (Sigma-Aldrich) and 
incubated for 2 min before stopping the reaction with 50 μl of 1 N HCl. The 
absorbance (A450) was measured by using a VICTOR X3 Multilabel Plate 
Reader (PerkinElmer) and the data were analyzed by using a spreadsheet 
program (Microsoft Office Excel).  
ELISA assays for the immunoRNases ware performed on ErbB2-
positive SKBR3, KPL4 and JIMT-1 breast cancer cells, NCI-N87, MKN7 
and AGS gastric tumor cells  and ErbB2-negative A431 control cells 
incubated in the absence or in the presence of increasing concentrations (2,5 
nM, 5 nM, 10 nM, 25 nM or 50nM) of each immunoRNase (ERB-HP-RNase 
or ERB-HP-DDADD-RNase) as described above. 
ELISA assays with Erb-hcAb were carried out on ErbB2-positive 
gastric tumor cells mentioned above, incubated with increasing 
concentrations of the antibody. Washes and incubations with the secondary 
antibody were performed as described above (50).  
For detection of the IR or the human antibodies, a mouse HRP-
conjugated anti-His monoclonal antibody (Qiagen) or a goat HRP-conjugated 
anti-human Fc monoclonal antibody (Immuno Reagents, Inc.) were used, 
respectively. 
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13. Competitive Cell ELISA 
To determine  whether the novel mAbs recognize  different Claudin-1 
epitopes, competition experiments were carried out by cell ELISA. Positive 
CLDN-1 cells, detached with non-enzymatic cell dissociation solution 
(Sigma-Aldrich) were blocked in PBS/BSA 6%, plated in a 96 multiwell 
plate (1 x 105 cells for each well) and incubated for 90 minutes with 200 nM 
of each mAb in PBS/BSA 3% in agitation at room temperature. Then the 
cells were resuspended in 100 µl of each scFv-phage (1 x 1011 cfu) prepared 
in a PBS/milk 2,5 % solution and incubated for further 2 hours in agitation at 
room temperature.  For the detection of bound phages, cells were incubated 
for 1 hour with a mouse HRP-conjugated anti-M13 monoclonal antibody (GE 
Healtcare). After extensive washes, cells were resuspended and analyzed  as 
described above.  
 
14. Cell lysis, Immunoprecipitation and Western Blot Analyses for anti-
CLDN-1 mAbs 
Claudin-1 positive cells (2,5 x 107), detached with non-enzymatic cell 
dissociation solution (Sigma-Aldrich), were resuspended in 1,5 ml of lysis 
buffer [10 mM of Tris HCl pH 7.4, 150 mM NaCl and 1% NP40] containing 
complete EDTA-free protease inhibitor (Roche Diagnostic). After 45 minutes 
at 0°C the extracts were clarified by centrifugation at 12000 rpm for 20 
minutes. Each cell lysate was incubated with 20 µl of Protein-A Sepharose 
(Sigma-Aldrich) for 1 hour by gently rotation at 4°C. After a centrifugation at 
2000 rpm for 5 minutes, the supernatant was incubated at 4°C for 16 hours by 
gently rotation with 5 µg of mouse anti-C-terminal region of Claudin-1 
monoclonal antibody (Life Technology, Inc.), 5 µg of rabbit anti- loop 1 of 
Claudin-1 polyclonal antibody, (Abcam) or 10 µg of each mAb selected by  
phage display. Each immune-complex was then collected by adsorption to 
Protein-A Sepharose for 1 hour at 4°C. After four washes and a 
centrifugation at 2000 rpm for 5 minutes, the proteins released by boiling in 
loading buffer (71) were loaded on 7,5% SDS-PAGE and electroblotted onto 
Nitrocellulose Transfer Membrane (Whatman GmbH, Dassel, Germany). The 
Claudin-1 protein was detected by using a mouse anti-C-terminal region of 
Claudin-1 monoclonal antibody (Life Technology, Inc.), as previously 
described (72). 
 
15. HCVcc generation and neutralization assays 
All chimeras were produced as previously described (73). Neutralization 
assays were performed by seeding Huh 7.5 cells (1.5 × 105) in a 96-well plate 
(BD Biosciences). After 24 h, each monoclonal antibody was added at the 
stated concentrations to cells, incubated for 1 h at 37°C in a humidified 
atmosphere containing 5% CO2, and washed twice with PBS. Virus was then 
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added and incubated at 37°C in a humidified atmosphere containing 5% CO2, 
for 72 h. Percentage of infected cells in the presence of antibodies was 
determined by comparison to the number of cells infected in the absence of 
inhibitors, as determined by NS5A staining (74). 
 
16. Cell viability and Cytotoxicity assays 
Huh-7.5 cells were seeded in 96-well flat-bottom plates at a density of 1 
x 104/well and incubated in a humidified incubator at 37°C with 5% CO2 for 
16 hours. After the addition of 100 or 500 nM of mAbs in the culture 
medium, cells were incubated for 72 hours  in the same conditions. Viable 
cells were counted by the trypan blue exclusion test at suitable time intervals. 
Cell survival was expressed as percent of viable cells in the presence of the 
monoclonal antibody under test with respect to negative control cultures 
grown in the absence of the protein. Typically, cell survival values were 
obtained from at least three independent experiments in which triplicate 
counts were determined; standard deviations were less than 5 %. Cell lysis 
was determined by measuring the release of lactate dehydrogenase (LDH) 
using a LDH detection kit (Roche Diagnostic). Lysis was calculated as the 
percent of cytolysis measured in the presence of each  mAb, taking as 100% 
the maximal LDH release determined by lysis of target cells treated with 1% 
Triton X-100. 
 
17. Expression and purification of ERB-HP-DDADD-RNase 
Cultures of E. coli BL21 DE3, previously transformed with the 
recombinant pET22b+ expression vector, were grown at 37°C in LB medium 
containing 50 µg/ml ampicillin until the exponential phase was reached. For 
the expression of soluble IR, 1 mM isopropyl-β-D-thiogalactopyranoside 
(IPTG, Applichem GmbH) was added to the cell culture, which then was 
grown at room temperature for 4 h. The cells were harvested by 
centrifugation at 6000 rpm for 15 min at 4°C.  
For the purification of the protein, the periplasmic extract, obtained by 
resuspending the bacterial pellet in B-PER® buffer (Pierce, Thermo Fisher 
Scientific, Rockford, IL, USA), was loaded on an immobilized-metal affinity 
chromatography (IMAC) by incubation with cobalt-chelating resin 
(TALON®; Clontech, Palo Alto, CA) at 25°C for 2h by gently rotation. After 
extensive washes in an appropriate buffer (PBS, 0.16 M NaCl, 20 mM 
imidazole), the elution step was performed in the same buffer containing a 
higher concentration of imidazole (250 mM). The concentration of the 
purified protein was determined by BCA Protein Assay kit (Pierce, Thermo 
Fisher Scientific) and the purity of the final preparations was  evaluated by 
SDS-PAGE and following staining with Coomassie blue solution (20% 
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isopropanol, 10% acetic acid, 0.1% Coomassie blue) and by western blotting 
analyses with a mouse HRP-conjugated anti-His antibody as described above. 
 
18. RNase activity and inhibition assays 
RNase activity was tested by the acid-insoluble RNA precipitation 
assay as described previously (75) on yeast RNA (8 mg/ml). Yeast RNA was 
incubated with the enzyme under test in the reaction buffer (50 mM Tris-
HCl, pH 8.0 containing 0.15 M NaCl) at 37°C for 30 min. The reaction was 
stopped and undegraded RNA was precipitated by addition of 10% cold 
perchloric acid containing 0.25% uranyl acetate. After incubation on ice for 
15 min, the samples were centrifuged at 12000 rpm for 15 min at 4°C and  the 
absorbance at 260 nm of the supernatant was determined. In this assay one 
unit of enzymatic activity is defined as the amount of enzyme that generates 
an increase of 1 OD at 260 nm.  
For the inhibition assays, appropriate amounts of ERB-HP-RNase or 
ERB-HP-DDADD-RNase were pre- incubated with increasing concentrations 
of RI (Promega) in the presence of 2mM DTT at 37°C for 10 min before 
starting the activity test as described above (76).  
 
19. Cellular internalization assays 
ErbB2-positive SKBR3 cells and JIMT1 cells resistant to Herceptin 
were seeded in 6-well flat-bottom plates at a density of 6 x 105/well and 
grown at 37°C for 24 h in culture medium. After the addition of an 
immunoRNase at a concentration of 200 nM, cells were incubated for 2 h at 
37°C. Cells were then washed extensively with a stripping solution of 50 mM 
glycine buffer, pH 3.0, containing NaCl (1.0 M), harvested with cell 
dissociation solution and treated as previously described (Borriello et al., 
2011). Internalized Erb–HP-RNase or Erb–HP-DDADD-RNase was detected 
by using appropriate dilutions of the anti-HPRNase antibody, followed by a 
HRP-conjugated anti-rabbit antibody. The signal intensity of the reactive 
bands was measured with a phosphorimager (45–710; Bio-Rad, Hercules, 
CA, USA). 
 
20. Effects of Erb-hcAb on tumor cell growth 
Gastric tumor cells were seeded in 96-well, flat-bottom plates at a 
density of 7.5 x 103/well. After addition of the protein under test, viable cells 
were counted by the trypan blue exclusion test at suitable time intervals. Cell 
survival was expressed as percent of viable cells in the presence of the 
monoclonal antibody under test with respect to negative control cultures 
grown in the absence of the protein. 
Growth inhibition of gastric tumor cells was assessed by using the MTS 
assay (Promega)  method  based on the bioreduction of 3-(4,5-
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dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium (MTS) by cells to a formazan product that is soluble in tissue 
culture media and  can be detected spectrophotometrically. For this assay, 
cells were seeded in 96-well plates in complete growth media. After 24 h, 
cell culture media were replaced with media containing 0.1 % fetal bovine 
serum (FBS) in the absence or in the presence of Erb-hcAb, which was added 
at concentrations ranging from 2 to 500 nM. At day 1, 2, or 3, aliquots of 
MTS (Promega)  (20 µl) were added to each well and plates were incubated 
at 37°C for 2–3 h. The reaction was monitored by measuring Absorbance at 
490nm. 
 
21. Effects of ERB-HP-DDADD-RNase on tumor cell growth  
Cells were seeded in 96-well flat bottom plates, ErbB2-positive SKBR3 
control cells at a density of 1.5 x 104/well, Herceptin-resistant JIMT-1 and 
A431 cells at 5 x 103/well, NCI-N87 and AGS cells at 1 x 104/well, and 
MKN-7 cells at 2 x 104/well. To test the effects of the immunoRNases on cell 
growth, SKBR3, A431, NCI-N87, MKN-7 and AGS cells were incubated at 
37°C for 72 h in culture medium in the absence or presence of increasing 
concentrations (25–100 nM) of the immunoRNase. The cell counts were 
determined in triplicate using the trypan blue exclusion test.  
 
22. In vivo antitumor activity of Erb-HP-DDADD-RNase 
The in vivo antitumor activity of Erb–HP-DDADD-RNase was 
determined  in Balb/cAnNCrlBR  athymic (nu/nu) mice (Charles River 
Laboratories, Calco, Italy). Herceptin resistant JIMT-1 cells were suspended 
in sterile PBS and injected subcutaneously into mice at a density of  2 x 106 
cells/mouse. On Day 30, when tumors were clearly detectable, Erb–HP-
RNase or Erb–HP-DDADD-RNase was administered intraperitoneally five 
times at 72-h intervals to groups of 5 mice at doses of 1.2 mg kg–1 of body 
weight. Another group of control mice was treated with identical volumes of 
sterile PBS to monitor tumor development. Tumor volume (V) was 
calculated by the formula of rotational ellipsoid: V = A x B2/2, where A is the 
axial diameter and B is the rotational diameter as measured with a caliper.  
 
23. Effects of Erb-hcAb on ErbB2 Signaling pathway  
For the evaluation of the effects of Erb-hcAb on the expression and 
phosphorylation of proteins involved in the ErbB2 signaling pathway,  a 
Western blotting analysis of lysates from untreated or treated NCI-N87 cells 
was performed. Detection was carried out by using the following antibodies: 
rabbit anti-Akt antibody, rabbit anti-phospho-Akt antibody, rabbit anti-
p44/42 MAPK (Erk1/2) antibody,  rabbit anti-Phospho-p44/42 MAPK 
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(Erk1/2) (Thr202/Tyr204) antibody (All from Cell Signaling Technology, 
Inc.). 
 
24. ADCC tests 
NCI-N87 target cells were detached from culture dishes with a cell 
dissociation solution (Sigma), transferred to 96-well plates (7,000 cells/well), 
and incubated for 16 h at 37°C. Subsequently, PBMCs from a healthy donor 
were added at effector:target ratio 10:1 in the absence or presence of 
increasing concentrations of Erb-hcAb or Herceptin (5–200 nM) and 
incubated for 24–48 h at 37°C. Controls included target cells incubated in the 
absence of effector cells or in the presence of immunoagents alone. Tumor 
cell lysis was determined by measuring the release of lactate dehydrogenase 
(LDH) using a LDH detection kit (Roche Diagnostic) as described above.  
 
25. In vivo antitumor activity of Erb-hcAb 
In vivo experiments were performed with 6-week-old female Balb/c nude 
mice (Charles River Laboratories, Calco, Italy). NCI-N87 cells (2 x 106) were 
suspended in 0.2 ml sterile PBS and injected subcutaneously (day 0) in the 
right paw. At day 10, when tumors were clearly detectable, Erb-hcAb or 
trastuzumab dissolved in PBS was administered intraperitoneally to two 
different groups of six mice at doses of 5 mg/kg body weight, seven times, at 
72-h intervals. Another group of control mice was treated with identical 
volumes of sterile PBS. During the period of treatment, tumor volumes (V) 
were measured with a caliper and calculated by the formula of rotational 
ellipsoid V = A x B2/ 2 (A is the axial diameter and B the rotational 
diameter). SD values were less than 10 %.  
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RESULTS 
 
 
1. Human antiviral immunoagents for antiviral therapy 
 
 
1.1. Parallel selections of human scFvs on a panel of different Claudin-
1-positive cells 
 
Phage particles from Phagemid library were prepared as described in 
Materials and Methods. The strategy used for the isolation of anti-Claudin-1 
scFv-phages consisted in multiple selections with the use of different 
combinations of positive, i.e., antigen-bearing, and -negative cell lines. This 
approach was devised to guarantee an efficient selection of a large number of 
clones with a high specificity for Claudin-1. 
 In the first strategy, human hepatoma cells Huh7.5, naturally 
expressing high levels of Claudin-1 (CLDN-1), were used as antigen-positive 
cells in the selection and HEK 293 cells lacking CLDN-1, were used in a 
subtractive step. In the second combination, HEK 293 cells trasduced with 
human Claudin-1 and untrasduced HEK 293 were used as antigen-positive 
and antigen-negative cells, respectively.  
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Fig. 5 - Schematic representation of each selection round 
 
In the third, CHO cells transfected with the expression vector encoding 
Claudin-1 and untransfected CHO have been used as antigen-positive and -
negative cells, respectively. In all the selections the negative cells have been 
used to deplete the library of phage antibodies that bind to common cell 
surface antigens.  
In each selection round of the first two strategies, CLDN1-positive cells 
were incubated with the antibody phage display library (1013 cfu/ selection) 
pretreated with the counterpart negative cells (untrasduced HEK 293), as 
described in the Methods. After 16 hours of incubation at 4°C, cells were 
washed, phage bound to the cell surface were displaced and used to infect E. 
Coli TG1 for amplification and further rounds of selections (Fig. 5).  
Initially, two rounds of selection were performed either with Huh7.5 or 
with HEK t293-CLDN-1 cells in suspension. Positive phages, which 
selectively bound to a Claudin-1-positive cell line, were submitted to two 
additional rounds of selection, using either the same combination of cells or 
crossing the selection with the other one to further increase the  chance to 
select phages with a high degree of specificity for CLDN-1 (see Fig. 6). 
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Strategy 3 was performed by panning the library directly on adherent 
CHO-CLDN-1 cells after the subtraction of non-specific clones on adherent 
untrasfected CHO cells, in order to select scFv against Claudin-1 in its 
natural environment within intercellular contacts.  
 
 
Fig. 6 - Parallel and crossed selection on different cell lines 
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1.2.Analysis of positive clones 
The strategy used for the analysis of positive clones and the following 
production of fully human antibodies is shown in figure 7. 
 
 
Fig. 7 - Strategy for the clones analysis 
 
 Briefly, cell ELISA assays on CLDN-1 negative and positive cells 
were carried out to identify Claudin-1-positive clones after 3-4 selection 
rounds of each selection strategy. As shown in Fig. 8-A, we selected those 
clones that were capable to discriminate between CLDN-1-positive and –
negative cells. The positive clones (approximately 20%) were analyzed by 
PCR analysis to confirm the presence of the cDNA encoding the scFv (Fig. 
8-B). 
The DNA preparations from clones containing a specific CLDN-1-scFv 
were then sequenced by using the same primers already used for PCR (see 
Materials and Methods). 
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Fig. 8-A – Screening of CLDN-1 positive phages by cell ELISA on 
CLDN-1-positive and-negative cells.  
Fig. 8-B - Analysis by PCR of cDNA encoding scFv fragment (800 bp) 
from some positive clones  
 
 
1.3.Production of soluble scFvs 
To prepare the human scFvs as soluble molecules, the pHEN2 or 
pCANTAB phagemid vector containing the DNA encoding each scFv, was 
expressed in the bacterial strain SF110. After induction with isopropyl-1-
thio-D-galactopyranoside, a periplasmic extract was prepared as described 
previously (14). Because the DNA encoding the scFv was cloned into the 
A 
B 
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vector fused to a COOH-terminal hexahistidine sequence, the recombinant 
scFvs were purified by Immobilized-Metal Affinity Chromatography, as 
described in Materials and Methods. 
To verify whether the soluble anti-CLDN-1 scFvs retained the binding 
properties of the scFvs displayed on phages, the purified proteins were 
analyzed by ELISA on the same cell lines previously tested with the anti-
CLDN-1 scFvs in their phage format. The results  indicated that the anti-
CLDN-1 soluble scFvs selectively bind to the antigen bearing cells (data not 
shown). 
 
 
1.4.Production and purification of anti-CLDN- 1 mAbs 
The cDNAs encoding the scFvs showing optimal binding features have 
been converted to more stable antibody formats by subcloning the variable 
regions into two eukaryotic vectors for the expression of H (IgG4 isotype) 
and L chains and by transfecting the resulting recombinant vectors into 
EBNA 293 cells, as described in Materials and Methods. The secreted 
antibodies have been purified by protein A-affinity chromatography and 
analyzed by SDS-PAGE under reducing conditions (see Fig. 9). The purified 
antibodies were then tested in cell-based assays for selective binding to cells 
expressing Claudin-1 (data not shown). Six antibodies (named A2, B9x, 
D10x, E9C2, F7C2 and H9C1) with the best profile of binding have been 
selected for further analyses.  
 
Fig. 9 - Analysis by SDS-PAGE of purified anti-CLDN-1 mAbs carried 
out under reducing conditions 
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1.5.Characterization of anti-CLDN 1 mAbs 
To determine whether the selected antibodies were specific for 
Claudin-1, Western blotting analyses of HEK t293-CLDN-1 cell lysates 
previously immunoprecipitated with each mAb were carried out by using a 
commercial CLDN-1 specific antibody. All the six mAbs recognized a 
protein of about Mr 23,000, the molecular weight expected for Claudin-1. In 
the same experiment a protein corresponding to the same molecular size was 
recognized by the commercial murine anti-Claudin-1 mAb (Life technology, 
Paisley, U.K.). No bands were detected when an unrelated mAb  was used as 
a negative control or when untrasfected cells were used for the 
immunoprecipitation (Fig. 10). 
 
Fig. 10 - Western blotting analyses with the commercial murine anti-
Claudin-1 mAb of HEK t293CLDN-1 cell lysates previously 
immunoprecipitated with each indicated mAb. As controls were used: 
lysate from untrasduced HEK t293 cells; lysate from HEK t293CLDN-1 
cells before and after incubation with protein-A Sepharose; lysate of 
HEK t293CLDN-1 cells previously immunoprecipitated with the 
commercial murine anti-CLDN-1 mAbs (anti-C-term and or-loop); and 
HEK t293CLDN-1 cell lysate previously immunoprecipitated with an 
irrelevant IgG 
 
We then characterized the binding of the anti-CLDN-1 mAbs to 
Huh7.5, untrasduced Hek t293 or trasduced CLDN-1-HEK t293 cells. As 
shown in figure 11, all the antibodies bind with high affinity to CLDN-1 
positive cells with the only exception of E9C2 mAb which shows a lower 
affnity. The half-saturating concentrations (corresponding to the apparent 
Kd) for binding  to Claudin-1-positive cells were in the low nanomolar range 
(Fig. 12) demonstrating that A2, B9x, D10x, F7C2 and H9C1 mAbs, selected 
by phage display, bind with high affinity to CLDN-1 expressed on human 
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hepatocytes and on CLDN-1-trasduced cells whereas they show poor binding 
to control untrasduced cells, thus confirming their binding specificity for 
CLDN-1. 
 
Fig. 11 - Binding of the 6 anti-CLDN-1 mAbs to Huh7.5 (triangles), 
untrasduced HEK t293 (squares) and CLDN-1 HEK t293 trasduced cells 
(rhomboids) 
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Fig. 12 - The half-saturating concentration as measured by the binding 
curves of the 6 anti-CLDN-1 mAbs to HEK t293-CLDN-1 cell line 
 
To investigate whether the 6 different anti-CLDN-1 mAbs recognize 
similar or unrelated epitopes, we performed cross-competition ELISA 
experiments with the mAbs. Each anti-CLDN-1 mAb was pre- incubated with 
Huh7.5 cells at saturating concentration and then further incubated for 1 h in 
the absence or presence of the phages expressing each of the 5 remaining 
anti-CLDN-1 single chain variable fragments. All of the mAbs were unable 
to reduce the binding of phages expressing the other scFvs whereas they all 
strongly reduced the binding of the phages expressing their parental scFv, 
used as a control (see Fig. 13). 
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Fig. 13 – Schematic representation for the competitive binding of the six 
antibodies. The percentage of binding was calculated as the ratio of the 
absorbance (450 nm) of each bound detected phage in the absence or in 
the presence of the indicated antibody  
 
These results were confirmed by competitive ELISA assays performed 
by using each biotynilated antibody in the absence or in the presence of the 
other unlabeled antibodies. The detection of bound antibodies with a 
streptavidin conjugated secondary antibody confirmed that they do not 
compete (data not shown). 
 
 
1.6.Neutralization of HCV Infection by human Anti-CLDN-1 
Antibodies 
Neutralization assays were performed by using the six different 
monoclonal antibodies directed against Claudin-1 on four genotype 2 and a 
chimeric H77/JFH-1 isolates. Virus neutralization was performed at a starting 
concentration of 100 µg/ml, decreasing 5- fold to 0.032 µg/ml. Neutralization 
curves are shown in Figure 14. All the mAbs showed neutralization 
capabilities that varied with isolate as expected. D10x shows an IC50s of less 
than 20ug/ml against two isolates, JFH-1 and J6 (7.83 ug/ml and 17.26 ug/ml, 
respectively) and B9X has the lowest IC50 (5.73 ug/ml; JFH-1). These two 
antibodies were then used in combination, at equal concentrations, to see if 
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they were antagonistic, synergistic or additive. As shown in Fig. 15, they 
showed additive effects against all the isolates tested, as expected since  they 
target different epitopes, and thus they could have good clinical value due to 
minimising escape variants. 
 
 
Fig. 14 - Neutralization curves of six novel anti-claudin antibodies. 
Neutralization curves against 2B2.8 (inverted triangles), JFH-1 (cyrcles), 
J6 (squares), 2B1.1 (triangles) and H77/JFH-1 (rhomboids) with six anti-
claudin antibodies. All mAbs had neutralization capabilities against the 
four isolated tested. Antibody preparations were incubated at the 
indicated concentrations with Huh-7.5 cells for 1 h. Cells were 
thoroughly washed with PBS and virus was added to the cells. Infection 
was determined by staining for NS5A after 72 h 
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Fig. 15 - Combinatorial treatment of two different anti-claudin-1 mAbs. 
Neutralization curves of B9X (squares), D10X (triangles) and the 
combination of the two antibodies (in Red) 
 
1.7.Side Toxic Effects of Anti-CLDN-1 mAbs  
To address potential toxic effects of anti-CLDN-1 mAbs, we performed 
cell viability and lysis analyses on treated Huh7.5 cells. Following incubation 
of hepatoma cells with each of the anti-CLDN-1 antibody for 72 hours at 
37°C, tests based on MTT and LDH release were carried out. As shown in 
Fig. 16 no toxic effects were observed even when very high concentrations 
(500 nM) were used. 
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Fig. 16 - Cytotoxic effects on Huh-7.5 cells of the anti-CLDN-1 mAbs. In 
panels A and B are shown the percentages of cell lysis after incubation 
with each indicated anti-CLDN-1 mAb at a concentration of 100 and 500 
nM; as positive control, cells were treated with 1% triton X-100. In 
panels C and D the percentages of cell viability after 72 h of incubation 
with each indicated anti-CLDN-1 mAb are shown 
  
D 
B 
C 
A 
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2. Human immunoagents for cancer immunotherapy 
 
2.1.Expression and purification of the ImmunoRNase 
The expression and purification of the ImmunoRNase was performed 
as described in Materials and Methods. The protein eluted by affinity 
chromatography on Immobilized Metal Ion Affinity Chromatography 
(IMAC) was analyzed by SDS-PAGE followed by Coomassie staining (Fig. 
17-A) and by Western blotting analyses with a mouse HRP-conjugated anti-
His monoclonal antibody (Qiagen), as shown in figure 17-B. 
 
           
 
Fig. 17-A - SDS-PAGE analysis of purified ERB-HP-DDADD-RNase 
followed by Coomassie staining.  Lane 2, flow through; Lane 3, fractions 
eluted from the column; Lane 4, ERB-HP-RNase, used as a standard 
molecular we ight protein.  
Fig. 17-B - Western blotting analysis of purified ERB-HP-DDADD-
RNase detected with an anti-His antibody. Lane 5 and 6 as in Lane 3 and 
4, respectively 
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2.2.RNase activity and inhibition of ERB-HP-DDADD-RNase 
 
The RNase activity was tested by the acid- insoluble RNA precipitation 
assay, as described in Materials and Methods. The engineered immunoRNase 
(ERB-HP-DDADD-RNase) retains about 40% of the activity of the parental 
immunoRNase, with a specific activity of 110 U/nmol (Fig. 18). This result is 
in line with the data previously reported in literature (77) for the mutant (HP-
DDADD) and wild type RNases.  
 
Fig. 18 - Enzymatic activity of the immunoRNases (IR). Absorbance of 
soluble degradation products of ERB-HP-RNase (in Blue) or ERB-HP-
DDADD-RNase (in Red) 
The sensitivity of the engineered immunoRNase to inhibition by the 
human inhibitor (RI) was then tested by pre-incubating appropriate amounts 
of the immunoRNase with increasing concentrations of RI, as described in 
Materials and Methods. The immunoRNase ERB-HP-DDADD-RNase was 
found to be not susceptible to inhibition by RI, in contrast to the native 
immunoRNase ERB-HP-RNase, tested in parallel, which was found to be 
fully inhibited at RI/IR ratio of about 1 (Fig. 19). The percentage of 
inhibition was calculated as follows: % inhibition = 100 - (% activity in the 
presence of RI/activity in the absence of RI).  
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Fig. 19 - Effects of the RNase inhibitor (RI) on the enzymatic activity of 
the parental ERB-HP-RNase (in Blue) or the variant ERB-HP-DDADD-
RNase (in Red), measured at increasing RI/IR ratios 
 
2.3. Binding of ERB-HP-DDADD-RNase to ErbB2-positive human 
tumor cells 
 
The affinity of Erb–HP-DDADD-RNase for the ErbB2 receptor on 
gastric tumor cells was tested by cell ELISA assays, performed on NCI-N87, 
MKN7 and AGS cells. In a parallel assay, mammary SKBR3 or JIMT-1 
cells, expressing high or moderate levels of ErbB2 receptor, respectively, 
were used as positive controls, and epidermoid A431 cells, expressing very 
low levels of ErbB2, as a negative control (data not shown). The results, 
shown in Fig. 20, indicate that Erb–HPDDADD-RNase retains the specificity 
of the parental Erb–HP-RNase, binding with a similar high affinity to control 
SKBR3 and JIMT-1 cells. As for the gastric tumor cells, both 
immunoRNases bind to MKN7 and NCI-N87 with a high affinity, but do not 
recognize AGS cells. 
To investigate whether the differential binding of the immunoRNases 
to the three gastric cell lines was due to a differential expression of ErbB2 in 
these cells, a quantitative analysis of their ErbB2 levels was performed on 
lysates by western blotting with a commercial anti-ErbB2 mAb. As shown in 
Fig. 21, ErbB2 is expressed in the tested gastric cell lines NCI-N87 and 
MKN7 at levels comparable to those found in JIMT-1 breast cancer cells, 
though lower with respect to those detected in SKBR3 cells. No significant 
signal corresponding to the receptor was detected in AGS tumor cells, 
suggesting that these cells express very low levels of ErbB2. These results 
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indicate a positive correlation between the ErbB2 levels on a cell and the 
affinity of the immunoRNases for that cell. 
 
 
 
Fig. 20 - Binding curves of Erb–HP-RNase (dashed lines) or Erb–HP-
DDADD-RNase (black lines) to gastric NCI-N87 (triangles), MKN-7 
(circles) and AGS (squares) cell lines, as well as to breast SKBR3 
(rhomboids) and JIMT-1 (crosses) cell lines, used as positive controls  
 
 
Fig. 21 - Quantitative analysis by western blotting of ErbB2-receptor 
levels on gastric (NCI-N87, MKN-7, AGS and MKN-45) cell lines and 
breast cancer (SKBR3 and JIMT-1) cell lines. The A431 cell line from 
human epidermoid carcinoma was used as a negative control  
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2.4. Cytotoxic effects of ERB-HP-DDADD-RNase 
The antitumor effects of the immunoRNase were tested on gastric 
tumor NCI-N87, MKN-7 and AGS cells in comparison with those observed 
on other ErbB2-positive tumor cells from different tissues, such as mammary 
SKBR3 (positive control), JIMT-1 cells resistant to Herceptin and ErbB2-
negative epidermoid A431 tumor cells (negative control; data not shown). 
After a 72 h incubation at 37°C, cell survival was expressed as percentage of 
viable cells in the presence of an immunoRNase with respect to control cells 
grown in the absence of the protein. As shown in Fig. 22, Erb–HP-DDADD-
RNase was found to inhibit the growth of the gastric tumor cells tested in a 
dose dependent manner, showing a strong effect on the NCI-N87 cell line, 
even at low protein concentrations. This immunoRNase is toxic to MKN-7 
cells, albeit at a higher protein concentration, and more so than the parental 
Erb–HP-RNase. Similar results were obtained for mammary JIMT-1 cells, 
which express ErbB2 levels comparable to those of NCI-N87 and MKN-7 
cells, but lower than those of SKBR3 cells, which were found to be equally 
sensitive to both immunoRNases. No cytotoxic effects were detected on AGS 
cells, as expected from the low affinity of both immunoRNases to these cells. 
Indeed, all of the cytotoxicity data indicate a correlation between the level of 
ErbB2 expression by a tumor cell and its vulnerability to an immunoRNase.  
 
                                            
Fig. 22 - Cytotoxic effects of immunoRNases on tumor cells in vitro. 
Dose–response curves for gastric NCI-N87 (triangles), MKN-7 (circles) 
and AGS (squares) cell lines, as well as for breast SKBR3 (rhomboids) 
and Herceptin-resistant JIMT-1 (crosses) cell lines, treated for 72 h with 
Erb-HP-RNase (dashed lines) or Erb-HP-DDADD-RNase (black lines) 
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2.5.In vivo antitumor activity of Erb–HP-DDADD-RNase 
To evaluate the therapeutic effects of Erb–HP-DDADD-RNase, we 
used ErbB2-positive JIMT-1 cells, clinically resistant to Herceptin, for 
studies in vivo. As shown in Fig. 23, Erb–HPDDADD-RNase reduces tumor 
volume substantially, whereas Erb–HP-RNase has a lesser effect. During 
treatment, the mice did not show signs of wasting or other visible signs of 
toxicity. Thus, we conclude that Erb–HP-DDADD-RNase exerts antitumor 
effects stronger than those of the parental immunoRNase, consistent with its 
resistance to RI. 
 
 
Fig. 23 - In vivo effects of Erb–HP-DDADD-RNase (in Yellow) or Erb–
HP-RNase (in Red) on Herceptin-resistant JIMT-1 tumors induced in 
mice. Treated mice (n = 5) were injected with Erb–HP-RNase or Erb–
HP-DDADDRNase at five doses of 1,2 mg/Kg-1 of body weight. Control 
mice (n = 5) were treated with sterile PBS (in Blue) 
 
2.6.Binding of Erb-hcAb to tumor gastric cells 
To evaluate the therapeutic potential of the compact anti-ErbB2 
antibody on the gastric tumor cells mentioned above, ELISA assays on these 
cells with increasing concentrations of Erb-hcAb or Herceptin, were carried 
out to test their binding capacity. As shown in Fig. 24, the two antibodies 
were found to bind to the NCI-N87 and MKN-7 gastric cells tested with high 
affinities (see Fig. 24), whereas no significant binding to MKN-45 and AGS 
cells expressing low levels of ErbB2 was detected.  
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Fig. 24 - Binding curves  of Erb-hcAb (Black symbol) and Herceptin 
(Empty symbol)  to gastric cancer cells: NCI-N87 (in Red), MKN-7 (in 
Blue), MKN-45 (in Green), or AGS (in Yellow) cells 
 
 
2.7. In vitro effects of Erb-hcAb on gastric cancer cells 
The antitumor effects of the antibodies were tested on gastric tumor 
cells by incubating NCI-N87, MKN-7, MKN-45, and AGS cells in the 
absence or in the presence of increasing concentrations (50–200 nM) of Erb-
hcAb or Herceptin. After 72 h, cells were counted and their survival was 
expressed as percentage of viable cells in the presence of the protein under 
test, with respect to control cells grown in the absence of the protein. As 
shown in Fig.25, Erb-hcAb was found to inhibit the growth of ErbB2-
positive NCI-N87 and MKN-7 cells tested in a dose-dependent manner, 
showing a stronger effect with respect to Herceptin when high protein 
concentrations were tested. In contrast, no significant effects were observed 
when Erb-hcAb or Herceptin was tested on MKN-45 or AGS cells (Fig. 25) 
expressing very low levels of ErbB2 (see Fig. 21). These data clearly indicate 
the specificity of the antiproliferative activity of the anti-ErbB2 antibodies.  
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Fig. 25 - In vitro anti-tumor effects of Erb-hcAb or Herceptin on gastric 
cancer cells: NCI-N87 (in Red), MKN-7 (in Black),  MKN-45 (in Blue), 
or AGS (in Green) cell lines, treated for 72 h with the indicated 
antibodies 
 
 
2.8. Effects of Erb-hcAb on ErbB2 signaling  
We then evaluated by Western blotting analysis the effects of treatment 
with Erb-hcAb on the expression of proteins involved in the ErbB2 pathway 
in NCI-N87 cells. Erb-hcAb inhibited the phosphorylation of MAPK and Akt 
(Fig. 26), thus suggesting that it retains its ability to inhibit the ErbB2 
survival pathway in gastric tumor cells.  
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Fig. 26 - Effects on MAPK and Akt signaling in NCI-N87 tumor gastric 
cells, as exerted by Erb-hcAb. Reduction in p-Erk1/2 or p-Akt levels was 
normalized to total Erk2 or Akt, respectively, by phosphor imaging 
signals detected by Western blotting 
 
2.9.Antibody-dependent cellular cytotoxicity (ADCC) as induced by 
Erb-hcAb 
 
To determine the capacity of Erb-hcAb to trigger ADCC toward 
antigen-expressing NCI-N87 cells, the target cells were incubated for 24 or 
48 h with effector PBL in the absence or in the presence of increasing 
concentrations of Erb-hcAb or Herceptin, used as a positive control. As 
shown in Fig. 28, Erb-hcAb effectively lysed NCI-N87 target cells in the 
presence of PBL. The extent of lysis reached almost 35 % of treated cells, 
whereas Herceptin, used as a positive control, induced about 15–20 % lysis. 
The basal level of cytotoxicity was measured in the presence of PBL (Fig. 
27) or Erb-hcAb alone (data not shown). No effects were detected in parallel 
assays carried out with ErbB2-negative cells, such as A431 (data not shown), 
or when Erb-hcAb was replaced by the parental anti-ErbB2 scFv, lacking the 
Fc domain (data not shown). These results indicate the specificity of the  Erb-
hcAb-dependent cell-mediated cytolytic activity, clearly based on binding 
abilities of the immunoagent both to the cognate receptor with its antigen-
binding sites and to natural killer cells with its Fc effector domain.  
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Fig. 27 - Antibody-dependent cytotoxicity assays on NCI-N87 cells 
treated for 24 or 48 h with peripheral blood lymphocytes (PBL) as 
effector cells in the absence (in Black) or in the presence of Erb-hcAb (in 
Blue) or Herceptin (in Red) 
 
 
2.10. In vivo antitumor activity of Erb-hcAb 
 
For in vivo studies, Erb-hcAb was tested on human gastric NCI-N87 
cancer cells. The treatment of mice bearing NCI-N87 tumors with seven 
doses, at 72-h intervals, of 5 mg/kg-1 body wt of Erb-hcAb induced a 
significant reduction in tumor volume (Fig. 28). In parallel experiments, we 
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tested the effects of trastuzumab, administered as already indicated for Erb-
hcAb. Figure 28 shows that trastuzumab, in contrast to Erb-hcAb, showed 
only slight effects on NCI-N87 gastric tumors. No growth inhibition was 
observed in mice treated with PBS. During the period of treatment, the 
animals did not show signs of wasting or other visible signs of toxicity.  
 
 
 
 
Fig. 28 - In vivo antitumor effects of Erb-hcAb on gastric xenografts. 
Tumor growth was measured in mice inoculated subcutaneously with 
NCI-N87 cells from a human gastric tumor. Treated mice (triangles) 
were injected with Erb-hcAb at doses of 5 mg/kg body weight. Injections 
were repeated seven times at 72-h intervals. Control mice were treated 
with sterile PBS solution (rhomboids), or with equimolar doses of 
trastuzumab (squares) 
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 DISCUSSION 
 
 
1. Human antiviral immunoagents 
 
Hepatitis C virus (HCV), the prototypical member of the Hepacivirus 
genus within the Flaviviridae family, is a blood-borne pathogen that affects 
approximately 3% of the global population. Approximately 60%–80% of 
infections lead to hepatitis C, a chronic degenerative disease of the liver, 
which can progress over time to liver fibrosis, steatosis, cirrhosis and 
hepatocellular carcinoma (HCC). HCV is associated with the majority of 
newly diagnosed hepatocellular carcinomas in the United States (78, 79) and 
is currently the leading cause of liver transplants worldwide (19). 
 An HCV vaccine is not available and current therapies based on 
pegylated interferon-alpha and ribavirin are poorly effective, costly, toxic and 
have limited efficacy depending upon the infecting genotype. Telaprevir and 
Boceprevir are the drugs targeting  the virus protease, in clinical use since 
2011, that show side toxic effects. Furthermore, a rapid appearance of drug-
resistant viruses emerge during treatment (20 - 24), highlighting the need for 
combination therapies with agents targeting diverse viral and host cell 
pathways. 
Monoclonal antibodies are particularly attractive because they are a 
validated class of therapeutics with proven efficacy, safety in a number of 
clinical applications, and an established production process. Furthermore, 
with the advent of humanized or fully human mAbs, there are no risks of 
immune reaction against the antibody (80 – 83). Overall, human mAbs have 
superior safety and pharmacokinetic profiles than the current antivirals and 
emerging DAAs particularly in the highly susceptible population of HCV 
positive liver transplanted patients.  
Anti-viral strategies based upon biologics have been successfully 
established for other viruses. Clinical proof of concept has been obtained for 
the HIV fusion inhibitor Fuzeon (Enfuvirtive), a synthetic peptide that blocks  
HIV entry into target cells (84), and for a monoclonal antibody against the 
HIV CCR5 co-receptor (PRO-140) (85). Synagis (Palivizumab), a humanized 
monoclonal antibody against the fusion protein of the respiratory syncytial 
virus (RSV), is the current standard of care for the prevention of RSV 
infections in infants that are at high-risk because of prematurity or other 
medical problems such as congenital heart disease (86). In the case of 
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Hepatitis B virus (HBV) chronic patients undergoing liver transplant, the use 
of hepatitis B immune globulin (HBIG) after liver transplantation, concurrent 
with NUCs at the time of, or immediately after, liver transplantation, is 
considered to be the standard of care in order to prevent reinfection of the 
graft. 
A similar strategy could be adopted for the prevention of liver graft re-
infection in HCV LT patients. However, HCV displays a very high inter- and 
intra- individual genetic variability especially in the E1 and E2 envelope 
glycoproteins where neutralizing determinants are present. Therefore 
antiviral neutralizing antibodies are effective at best only against some viral 
variants (15). Accordingly, passive immunotherapy in LT patients with 
polyclonal or monoclonal antibodies against the viral envelope can only 
transiently lower RNA levels, but do not prevent re-infection presumably due 
to the large heterogeneity in the infecting viral population (25, 26). In 
addition, it was shown that HDL can reduce the neutralizing effect of anti-
HCV antibodies (27, 28), raising additional concerns about the efficacy of 
anti-HCV antibodies for active or passive immunotherapy.  
For the above mentioned reasons, the recent discovery of cell surface 
molecules required for HCV viral entry may offer a radically novel 
perspective for the development of new preventative and therapeutic agents. 
As an alternative to the development of anti-HCV antibodies, the 
development of anti-receptor antibodies are less likely to be prone to 
sequence changes in viral proteins.  
The human scavenger receptor class B type I (SRB1) is an essential 
receptor for HCV (29, 31, 87, 88). It has been shown that SRB1 is required 
for infection by different HCV subtypes (30, 88) supporting the hypothesis 
that the same SRB1 protein element is responsible for the recognition of 
different HCV E2 glycoproteins despite their high level of sequence 
variability. Furthermore, monoclonal antibodies (mAb) against native human 
SRBI block HCV virus infection of Huh7.5 hepatoma cells in a dose-
dependent manner (31).  Most importantly, the neutralization potency of 
these mAbs was not affected by HDL (31), suggesting that an anti-HCV 
immunotherapy based on human antibodies against SRB1 may overcome the 
problem of desensitization of HCV neutralization by antibodies against the 
virus. 
An alternative target for the anti-HCV immunotherapy is the tight 
junction protein CLDN-1, essential for the late step of virus entry, spread and 
persistence of HCV infection (9). Recently, rat monoclonal antibodies against 
CLDN1 have been produced by using genetic immunization. These anti-
CLDN-1 mAbs have been found to be effective for inhibition of all major 
genotypes as well as highly variable HCV quasispecies isolated from 
individual patients, blocking cell entry of highly infectious escape variants of 
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HCV that were resistant to neutralizing antibodies (34). However, a full 
success of present-day immunotherapy could be still hindered by immune 
response against non-human, or even humanized antibodies. 
Thus, to generate human monoclonal antibodies against CLDN-1 we 
selected single chain (scFv) libraries displayed on filamentous bacteriophage 
M13 by using a subtractive selection strategy based on the use of several 
different combinations of CLDN-1 -positive and -negative cell lines devised 
to guarantee the selection of a large number of clones with high specificity 
for CLDN-1. Phage binders showing the highest degree of specificity for 
CLDN-1 were converted into whole human IgG4. The IgG4 isotype was 
chosen because it lacks ADCC or ability to mediate NK and complement 
activity. Furthermore, IgG4 have longer half- life. 
Six human anti-CLDN-1 mAbs, named A2, B9x, D10x, E9C2, F7C2 
and H9C1, were further characterized and found capable to selectively bind 
to CLDN1-positive cells with a variety of different affinities ranging from 
about 100 down to 0.3 nM. 
All the antibodies were capable to potently inhibit cell entry of different 
HCV isolates in a dose-dependent manner. However surprisingly there was 
no correlation between their binding affinities and their neutralization 
efficacy as the best binder F7C2 (Kd=0.3 nM) showed similar inhibitory 
effects (EC50= 20-60 µg/mL) when compared to those of E9C2 (Kd=117 
nM), and the two most potent antibodies were found to be B9X and D10X  
with an EC 50 down to 6 µg/mL even though their affinities are not the 
highest, being 13.1 and 2.9 nM, respectively.  
This finding can be explained by considering that these antibodies 
recognize different epitopes of CLDN1 and thus could have different 
mechanisms of action, thus allowing for combinatorial treatment. Indeed an 
increased antiviral potency has been observed when the two antibodies B9x 
and D10x, were used in combination, thus suggesting that their effects are at 
least additive. 
Interestingly, the doses of these human anti-CLDN1 mAbs required for 
efficient inhibition (EC50 of 5–50 µg/mL) were similar to those observed for 
the six rat anti-CLDN-1 antibodies mentioned above, that on the contrary 
cannot be used in combinatorial treatment as they all recognize a similar 
epitope.  
It is noteworthy that these concentrations are lower than those used in 
clinic for antibody anti-HBs (hepatitis B virus surface antigen) required for 
prevention of HBV infection (100-500 µg/ml) after liver transplantation (89), 
and in a similar range of approved therapeutic mAbs used in cancer or 
antiviral treatment (90, 91), allowing for the possibility to use these 
antibodies in clinical therapy. 
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On the basis of these results we can conclude that these novel fully 
human anti-CLDN-1 antibodies may provide new anti-HCV therapeutic 
opportunities either in monotherapy or in combination with other antibodies 
targeting different HCV receptors or other novel anti-viral drugs to increase 
the number of responders and to prevent re- infection after liver 
trasplantation. 
 
 
 
 
2. Human immunoagents for cancer therapy 
 
Immunotherapy is a valid alternative strategy in anti-cancer therapy, 
useful to overcome the limits of the conventional therapeutic approaches, 
currently used, such as chemotherapy and radiotherapy. The ErbB2 receptor, 
highly expressed on many tumor cells of different origin, especially in human 
breast cancer, is an attractive tumor target.  
The first ErbB2-targeted therapeutic immunoagent approved by FDA is 
Herceptin, a humanized monoclonal antibody widely used for 
immunotherapy of ErbB2-positive breast cancer. However it can engender 
cardiotoxicity, and a high fraction of breast cancer patients is resistant to 
Herceptin treatment. For these reasons, novel anti-ErbB2 immunoagents, 
such as Erb-hcAb and ERB-HP-DDADD-ImmunoRNase, have been 
generated in our laboratory by using a human scFv selected by phage display 
technology. These novel immunoagents were found to bind selectively to 
tumor cells expressing ErbB2 and to inhibit their growth in vitro and in vivo, 
with no effects on ErbB2-negative cells. In this study we investigated their 
therapeutic effects on gastric tumor cells and on breast cancer cells less 
sensitive or fully resistant to Herceptin treatment, respectively.  
We demonstrate that Erb-hcAb is effective on gastric cancer cell lines 
with ErbB2 overexpression, showing an antitumor effect more potent than 
that observed for Herceptin. These differences could be explained by the 
recent interesting finding that Erb-hcAb recognizes an epitope different from 
that recognized by Herceptin (48, 92). Moreover, our data show that Erb-
hcAb induces both ADCC and apoptosis of these cells (93). 
Similar antitumor efficacy has been for ERB-HP-DDADD-RNase, a 
novel fully human immunoRNase targeting the ErbB2 receptor. This 
immuno-conjugate, made up of Erbicin and a RNase variant resistant to the 
inhibitor, retains about 40% of the enzymatic activity of the parental  
immunoRNase but, at difference with the latter, it is fully resistant to RI 
inhibition. Indeed, ERB-HP-DDADD-RNase inhibits selectively and 
efficiently the growth of Herceptin-resistant breast and gastric cancer cells in 
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vitro and in vivo with a more potent cytotoxic action with respect to that of 
the parental ERB-HP-RNase. This different toxicity is highlighted when the 
proteins are tested on cell lines with a lower expression of ErbB2 receptor, in 
which a less efficient internalization of the immunoRNases in the cytosolic 
compartment does not affect the cytotoxicity of the engineered RI-resistant 
ERB-HP-DDADD-RNase, whereas it leads to fully inhibition of the parental 
ERB-HP-RNase.  
In conclusion, these results indicate that both Erb-hcAb and ERB-HP-
DDADD-RNase confirm their potential therapeutic effect, proving that they 
could be useful for the treatment of different types of carcinomas less 
sensitive or resistant to Herceptin treatment.  
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